A review of health technology appraisals: Case studies in oncology

International Journal of Technology Assessment in Health Care

Volumn 29, Issue 1, 2013, Pages 101-109

  Shah, Koonal Kirit ^a   Mestre Ferrandiz, Jorge ^a   Towse, Adrian ^a   Smyth, Emily Nash ^b  

^a OFFICE OF HEALTH ECONOMICS   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Breast cancer; Colorectal cancer; Health technology assessment; Oncology; Pharmaceuticals

Indexed keywords

BREAST CANCER; COLORECTAL CANCER; FINANCIAL CONSTRAINTS; GLOBAL ECONOMIC CRISIS; HEALTH OUTCOMES; HEALTH TECHNOLOGY; HEALTH TECHNOLOGY ASSESSMENTS; PATIENT HEALTH; PHARMACEUTICAL MANUFACTURERS; RESEARCH AND DEVELOPMENT; VALUE FOR MONIES;

DISEASES; DRUG PRODUCTS; MANUFACTURE; ONCOLOGY; PROFITABILITY;

PATIENT TREATMENT;

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LETROZOLE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; RALTITREXED; TEGAFUR; TRASTUZUMAB; URACIL;

ADVANCED CANCER; AUSTRALIA; BREAST CANCER; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; FRANCE; HEALTH CARE; HUMAN; MEDICAL TECHNOLOGY; OVERALL SURVIVAL; QUALITY OF LIFE; REVIEW; UNITED KINGDOM;

ADVISORY COMMITTEES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DECISION MAKING; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME;

EID: 84874470510     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462312000669     Document Type: Review

References (19)

1. Wilking N, Jonsson B, Hogberg D. Comparator Report on Patient Access to Cancer Drugs in Europe. Stockholm: Karolinska Institutet and Stockholm School of Economics; 2009
2. BerryDA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-92
3. Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. The impact of mammography and adjuvant therapy on U.S. breast cancer mortality (1975-2000): Collective results from the cancer intervention and surveillance modeling Network. J Natl Cancer Inst. 2006;36:1-126
4. Sun E, Jena AB, Lakdawalla D, et al. The contributions of improved therapy and earlier detection to cancer survival gains, 1988-2000. Forum for Health Econ Policy. 2010;13:1-20
5. Association of the British Pharmaceutical Industry (ABPI). Target Breast Cancer. London: ABPI; 2005
6. European Medicines Agency. [cited 2011 November 21]. Available from: Http://www.ema.europa.eu.
7. Kanavos P, Schurer W. The burden of colorectal cancer: Prevention, treatment and quality of services. Eur J Health Econ. 2010;10:S1-S3
8. International Society for Pharmacoeconomics and Outcomes Research. [cited 2011 November 21]. Available from: Http://www.ispor.org/.
9. MOHLTC. Ontario Drug Benefit. [cited 2011 November 23]. Available from: Http://www.health.gov.on.ca/english/providers/program/drugs/dr- glossary/glossary-I.html
10. Kanavos P, Nicod E, van den Aardweg S, Pomedli S. The impact of health technology assessments: An international comparison. Euro Observer. 2010;12:1-9
11. McCabe C, Bergmann L, Bosanquet N, et al. Market and patient access to new oncology products in Europe: A current, multidisciplinary perspective. Ann Oncol. 2009;20:403-12
12. Axelrod RC. The significance of progression free survival as a clinical end point in oncology. Drug Benefit Trends. 2010;22
13. Saad ED, Katz A, BuyseM. Progression-free survival as surrogate and as true end point: Insights from the breast and colorectal cancer literature. Ann Oncol. 2010;21:7-12
14. European Medicines Agency. Assessment Report for AVASTIN. London: European Medicines Agency; 2011
15. Aaronson NK, Ahmedzai S, BergmanB, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76
16. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol. 1993;11:570-9
17. Messina J, Grainger DL. A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicines. Patient. 2012;5:199-211
18. Roch́eH, Fumoleau P, Spielman M, et al. 6 cycles of FEC 100 followed by 3 cycles of docetaxel for node-positive breast cancer patients: Analysis at 5 years of the adjuvant PACS 01 trial. Paper presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, 2004
19. Clement FM, Harris A, Li JJ, et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: A comparison of Britain, Australia, and Canada. JAMA. 2009;302:1437-43